A carregar...
Deep AR suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure
BACKGROUND: Enzalutamide and apalutamide are potent next-generation androgen receptor (AR) antagonists used in metastatic and non-metastatic prostate cancer. Metabolic, hormonal and immunologic effects of deep AR suppression are unknown. We hypothesized that enzalutamide and apalutamide suppress 11β...
Na minha lista:
| Publicado no: | Ann Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7460727/ https://ncbi.nlm.nih.gov/pubmed/32057540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.annonc.2019.12.002 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|